Evaluation of general features of patients with testicular cancer

Basit Öğe Kaydı
dc.authorid0000-0002-6839-2632
dc.authorid0000-0002-9861-4849
dc.authorid0000-0002-3982-7465
dc.contributor.authorGülseven, Merve Erol
dc.contributor.authorÜyetürk, Ümmügül
dc.contributor.authorGeredeli, Çağlayan
dc.date.accessioned2021-06-23T18:43:00Z
dc.date.available2021-06-23T18:43:00Z
dc.date.issued2020
dc.departmentBAİBÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.description.abstractObjective: Testicular cancers (Tca) are most common in men aged 20-34. Despite the increase in its incidence, the mortality rate from Tca decreases. In our study, it was aimed to evaluate the general characteristics, the treatments and survival of the patients who were followed up and treated with the diagnosis of Tca. Materials and Methods: In this study, patients who were admitted to Okmeydanı Training and Research Hospital and Abant İzzet Baysal University, Medical Faculty, Medical Oncology Outpatient Clinic between January 2004 and December 2014 with the diagnosis of Tca, were evaluated retrospectively. Results: In 324 (96.7%) of 332 patients included in the study with the diagnosis of Tca, testicular germ cell tumor (TGCT) was present. Of the patients, 150 (46.3%) had seminoma and 174 (53.7%) had non-seminoma tumors. The median age of patients with TGCT was 32 (minimum 18-maximum 81) years. Non-seminoma group was diagnosed at a younger age (p<0.05). The most common histology in the non-seminoma group was mixed germ cell tumor which was found in 135 patients (77.6%). The stage in which the patients were most diagnosed was stage I (seminoma 73.3% and non-seminoma tumor 44.3%, p<0.001). Distant metastasis was present in 3.5% of patients with seminoma and 32.7% of patients with non seminoma tumor (p<0.001). It was observed that 98% of the patients in the seminoma group and 85.6% of the patients in the non-seminoma group were in the good prognostic group (p<0.001). Radiotherapy, which was applied in 90 (81.8%) patients, was the most applied treatment in the group with stage I seminoma. In stage I non-seminomatous group, the most common treatment was cisplatin-based combination treatments, which was given to 58 (75.3%) patients. The median follow-up period of patients with stage I seminoma was 60 (minimum 3-maximum 134) months, and the median follow-up period of patients with non-seminoma tumor was 69 (minimum 8-maximum 178) months. Three hundred twelve (96.3%) patients with TGCT survived and 145 (96.7%) in the seminoma group and 167 (96%) patients in the non-seminoma group survived (p>0.05). Conclusion: The majority of our patients were diagnosed at an early stage and were in the good prognostic group. Most of our patients survived during our followup period.en_US
dc.identifier.doi10.4274/uob.galenos.2020.1458
dc.identifier.endpage145en_US
dc.identifier.issn2147-2122
dc.identifier.issn2147-2270
dc.identifier.issue3en_US
dc.identifier.startpage141en_US
dc.identifier.trdizinid366405en_US
dc.identifier.urihttps://doi.org/10.4274/uob.galenos.2020.1458
dc.identifier.urihttps://app.trdizin.gov.tr/makale/TXpZMk5EQTFOUT09
dc.identifier.urihttps://hdl.handle.net/20.500.12491/3718
dc.identifier.volume19en_US
dc.identifier.wosWOS:000562705900010en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.institutionauthorÜyetürk, Ümmügül
dc.language.isoenen_US
dc.relation.ispartofÜroonkoloji Bültenien_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectSurvivalen_US
dc.subjectTesticular Cancer
dc.subjectTesticular Germ Cell Tumor
dc.titleEvaluation of general features of patients with testicular canceren_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
merve-erol-gulseven.pdf
Boyut:
286.85 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam metin/Full text
İndir

Koleksiyon

TR-Dizin İndeksli Yayınlar Koleksiyonu
Dahili Tıp Bilimleri Bölümü Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu